Harrow (NASDAQ:HROW) and Vivani Medical (NASDAQ:VANI) Head to Head Survey

Vivani Medical (NASDAQ:VANI) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vivani Medical and Harrow, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1	1	1	0	2.00
Harrow	1	2	8	0	2.64

Vivani Medical currently has a consensus price target of $3.50, indicating a potential upside of 204.35%. Harrow has a consensus price target of $69.43, indicating a potential upside of 61.95%. Given Vivani Medical’s higher probable upside, equities research analysts plainly believe Vivani Medical is more favorable than Harrow.

Insider and Institutional Ownership

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 53.3% of Vivani Medical shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Vivani Medical and Harrow’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-264.04%	-79.85%
Harrow	-5.57%	19.59%	2.26%

Earnings & Valuation

This table compares Vivani Medical and Harrow”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61 million	($0.40)	-2.88
Harrow	$268.68 million	5.95	-$5.14 million	($0.41)	-104.56

Harrow has higher revenue and earnings than Vivani Medical. Harrow is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vivani Medical has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Summary

Harrow beats Vivani Medical on 7 of the 13 factors compared between the two stocks.

About Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.